Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 4, 2025

TFAP2C (transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)) Antibody (against the middle region of TFAP2C) (50ug)

RRID:AB_2046815
Type: Antibody

Proper Citation

(Aviva Systems Biology Cat# ARP33433_P050, RRID:AB_2046815)

Antibody Information

URL: http://antibodyregistry.org/AB_2046815

Proper Citation: (Aviva Systems Biology Cat# ARP33433_P050, RRID:AB_2046815)

Target Antigen: TFAP2C (transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)) (against the middle region of TFAP2C) (50ug)

Host Organism: rabbit

Clonality: unknown

Comments: manufacturer recommendations: Western Blot; WB

Antibody Name: TFAP2C (transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)) Antibody (against the middle region of TFAP2C) (50ug)

Description: This unknown targets TFAP2C (transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)) (against the middle region of TFAP2C) (50ug)

Target Organism: chicken, rat, xenopusamphibian, porcine, canine, pig, mouse, chickenbird, zebrafishfish, bovine, zebrafish, human, dog

Antibody ID: AB_2046815

Vendor: Aviva Systems Biology

Catalog Number: ARP33433_P050

Record Creation Time: 20231110T072051+0000

Record Last Update: 20241115T125449+0000

Ratings and Alerts

No rating or validation information has been found for TFAP2C (transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)) Antibody (against the middle region of TFAP2C) (50ug).

No alerts have been found for TFAP2C (transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)) Antibody (against the middle region of TFAP2C) (50ug).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Flippo C, et al. (2022) Precocious Puberty in a Boy With Bilateral Leydig Cell Tumors due to a Somatic Gain-of-Function LHCGR Variant. Journal of the Endocrine Society, 6(10), bvac127.